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Summary: In this randomized trial of screening for tuberculosis among adults in rural 
Malawi with newly-diagnosed HIV, all-cause mortality was 22% lower overall, and 57% 
lower among participants with clinically advanced HIV, when using point-of-care Xpert 
MTB/RIF versus point-of-care fluorescence microscopy. 
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ABSTRACT 
Background: Tuberculosis (TB) remains the leading cause of death among HIV-positive 
individuals globally. Screening for TB at the point of HIV diagnosis with a high-sensitivity 
assay presents an opportunity to reduce mortality. 
Methods: We performed a cluster randomized trial of TB screening among adults newly 
diagnosed with HIV in 12 primary health clinics in rural Thyolo, Malawi (clinicaltrials.gov 
NCT01450085). Clinics were allocated in a 1:1 ratio to perform either point-of-care 
Xpert MTB/RIF (Xpert) or point-of-care light-emitting diode fluorescence microscopy 
(LED FM) for individuals screening positive for TB symptoms. Asymptomatic 
participants were offered isoniazid preventive therapy in both arms. Investigators, but 
not clinic staff or participants, were masked to allocation. Our primary outcome was the 
incidence rate ratio (RR) of all-cause mortality within 12 months of HIV diagnosis.  
Results: Prevalent TB was diagnosed in 24 (2.4%) of 1001 individuals enrolled in clinics 
randomized to Xpert, versus 10 (1.2%) of 841 in clinics randomized to LED FM. All-
cause mortality was 22% lower in the Xpert arm than in the LED FM arm (6.7 versus 8.6 
per 100 person-years, RR 0.78; 95% confidence interval [CI]: 0.58-1.06). A planned 
subgroup analysis suggested that participants with more advanced HIV (World Health 
Organization clinical stage III or IV) disease had lower mortality in clinics randomized to 
Xpert than to LED FM (RR 0.43, 95%CI: 0.22-0.87).  
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Conclusion: In rural Malawi, using point-of-care Xpert MTB/RIF to test symptomatic 
patients for TB at the time of HIV diagnosis reduced all-cause 12-month mortality 
among individuals with advanced HIV.   
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INTRODUCTION 
Tuberculosis (TB) is the leading single-agent infectious cause of mortality and the 
leading cause of HIV-associated mortality worldwide.1 Xpert MTB/RIF (Xpert, Cepheid, 
Inc., Sunnyvale, CA, USA) is a molecular assay2,3 first recommended for TB diagnosis 
among HIV-positive individuals in 2010.4 Subsequent trials have compared Xpert, 
performed in central laboratories, against sputum smear microscopy among 
symptomatic patients.5-9 Although Xpert significantly improved same-day diagnosis in 
South Africa5 and shortened time to treatment in Brazil,7 a benefit on all-cause mortality 
has not been conclusively demonstrated.  
 
In most previous trials, the potential role of Xpert for active screening among HIV-
positive individuals was not investigated. One-year mortality remains ≥8% for individuals 
starting antiretroviral therapy (ART) in sub-Saharan Africa,10-12 and TB is the leading 
cause of death.13,14 A small randomized trial in Zimbabwe showed a non-significant 
reduction in three-month mortality (6% versus 10%) using Xpert versus sputum smear 
using light-emitting diode fluorescence microscopy (LED FM).15 We performed a cluster 
randomized trial of point-of-care (POC) screening for active TB among adults newly 
diagnosed with HIV in rural Malawi. Our primary hypothesis was that one-year all-cause 
mortality would be lower in clinics (clusters) provided with POC Xpert versus POC LED 
FM. 
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METHODS 
Study Population  
The CHEPETSA trial was a cluster randomized trial of POC TB screening in 12 primary 
health centers in rural Thyolo District, Malawi. Cluster randomization was used to 
minimize risks of contamination with this clinic-level intervention. Inclusion criteria for 
clinics included primary health center status, provision of HIV testing and ART, and 
sufficient patient volume. After receiving consent from clinic representatives and the 
Ministry of Health, eligible clinics were randomized (six clinics per arm) to TB screening 
using Xpert MTB/RIF on a single expectorated sputum specimen versus LED FM on 
two spot expectorated sputum specimens. All adults (≥18 years old) receiving a new 
diagnosis of HIV were screened for eligibility; allocation was based on clinic attended. 
Exclusion criteria were: (a) existing diagnosis of TB; (b) currently taking isoniazid 
preventive therapy (IPT); (c) currently taking treatment for active TB or HIV (i.e., ART); 
(d) unable to speak English or Chichewa; (e) not living in an area where follow-up would 
be feasible; and (f) refusal of written informed consent. Eligible participants were asked 
about four TB symptoms: cough of any duration, fever, night sweats, and severe weight 
loss; those reporting any symptom were tested for TB using Xpert or LED FM, 
according to cluster. The trial is registered on clinicaltrials.gov (NCT01450085).  
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Procedures 
Symptom screening and sputum evaluation were performed on-site by trained study 
personnel, and results were provided to participants on the same day. Participants 
testing positive for active TB were referred for treatment; those without TB symptoms 
were provided IPT (isoniazid 300mg daily plus pyridoxine 25mg daily). Participants with 
TB symptoms but negative Xpert or LED FM results were asked to return in one month 
and provided IPT at that time if asymptomatic. IPT was given for six months in 
accordance with World Health Organization (WHO) guidelines and was dispensed by 
study staff at initiation and after one and three months of treatment.  
 
In accordance with contemporary Malawian guidelines, all participants were seen by a 
(non-study) nurse or clinical officer for clinical staging; those with WHO stage III or IV 
disease (including any participants diagnosed with TB) were started immediately on 
ART. Participants with WHO stage I or II disease had CD4+ T-cell testing; those meeting 
CD4 count criteria (≤350 cells/mm3 until July 2014, then ≤500 cells/mm3 thereafter) 
were started on ART, at a subsequent visit. Participants not given ART had repeat CD4+ 
testing every six months. All CD4+ testing and HIV care was provided by non-study 
clinicians under routine conditions. 
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Our primary outcome was all-cause mortality within 12 months following HIV diagnosis. 
Secondary outcomes included TB treatment outcomes, TB incidence, and mortality in 
subgroups of age (≤35 versus >35 years old), sex, clinical stage (stage I/II versus III/IV), 
and ART eligibility/CD4 count. The ART threshold change to ≤500 cells/mm3 required us 
to alter a pre-specified subgroup analysis according to ART eligibility to one according 
to CD4+ T-cell count above or below 350 cells/mm3.   
 
All outcomes were assessed at the cluster level. All participants were asked to return to 
study clinics for assessment every three months (with one extra visit when on IPT); 
those who did not attend scheduled appointments were traced at their homes and 
through routine HIV clinic records. At each study visit, participants were screened for 
any TB symptom and tested using Xpert or LED FM if symptomatic. Point-of-care Xpert 
and LED FM were not available for routine TB diagnosis. Study staff underwent 
quarterly quality assessments of smear and Xpert procedures, with re-training as 
necessary.  
 
All patients with positive Xpert or LED FM results had sputum taken for confirmatory 
microscopy and culture (Mycobacteria Growth Indicator Tube, MGIT, BD Diagnostics, 
Sparks, MD, USA), performed at a central laboratory, and were referred for treatment 
through the routine healthcare system. Diagnoses of TB made outside of the study were 
reviewed by a study clinician (ELC). TB was defined as any diagnosis of 
Outcomes and Ascertainment 
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microbiologically confirmed active TB or initiation of active TB treatment, occurring at 
the time of the enrollment visit (prevalent) or afterward (incident). 
 
 
Study Sites, Randomization and Power 
Twelve study sites were initially selected based on volume of HIV diagnoses, presence 
of an ART delivery program, and geographic location. Most clinics did not have stable 
electricity; in the Xpert arm, solar panels and uninterrupted power supply were therefore 
installed to support Xpert testing before recruitment began. 
 
Randomization was constrained to provide balance on five variables: annual volume of 
HIV diagnoses, proportion of newly HIV-positive individuals who were pregnant, 
presence of ART initiation (versus delivery only), pre-randomization mortality among 
ART initiators, and study wave/geography (two clinics in each arm per wave, with waves 
selected prior to randomization based on geography). Randomization was performed by 
the study statistician (LHM) who identified all possible randomizations that would 
achieve the pre-specified balance criteria.16 In a public ceremony, a Ministry of Health 
official randomly selected one of the 50 possible (concealed) schemes, with allocation 
of Xpert versus LED FM determined by coin flip. Allocation was based on clinic/cluster; 
neither clinics nor participants were blinded to allocation, but investigators and central 
laboratory staff remained blinded to allocation until final unmasking. 
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Recruitment was conducted in three waves of four clinics each. Enrollment began on 
August 30, 2012, and ended on December 8, 2015; follow-up concluded on December 
20, 2016. Each wave consisted of one year of recruitment followed by one year of 
follow-up; follow-up for each wave overlapped with recruitment for the subsequent 
wave. The trial ended when the final wave of clinics completed the follow-up year. After 
randomization but before the start of recruitment, one study clinic stopped providing HIV 
care services and was replaced with the clinic that had the next-highest number of HIV 
diagnoses made in the previous year.  
 
The study was powered based on anticipated enrollment of 1800 participants per arm, 
with an estimated 80% power (Type I error of 5%) to detect a halving of mortality (4% 
versus 8%) in the Xpert versus LED FM arms, accounting for variability in clinic sizes 
(anticipated 200 to 700 participants) and a coefficient of variation of 0.25 (a common 
default value).17  
 
Actual enrollment was about half of anticipated enrolment, due primarily to lower 
numbers of individuals being diagnosed with HIV during the study period than in the 
preceding years.  This was a national phenomenon, reflecting the successful scale-up 
of antiretroviral therapy and a corresponding reduction in HIV incidence.   
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Statistical Analysis 
In each clinic, we calculated the mortality rate (number of deaths divided by total 
person-time). Contributed person-time was considered to end at the earliest of death, 
last documented contact, refusal to participate, or at 12 months (for those with 
documented contact at or after 12 months). In the primary analysis, we calculated the 
log mortality rate for each clinic, then took the difference of the means for each study 
arm and exponentiated to obtain the rate ratio, comparing Xpert to LED FM clinics. 
Secondary analyses included Poisson regression with multivariable adjustment18 and 
planned subgroup analyses according to age, sex, and WHO clinical stage (all factors 
associated with increased risk of prevalent TB and/or lower probability of subsequent 
follow-up). All subgroup analyses were adjusted for these other covariates. Statistical 
significance was assessed by Student’s t-test of the log rates at the clinic level and 
defined as a two-tailed p-value <0.05. Analyses were performed by the blinded study 
statistician (LHM). 
 
Ethical Considerations 
This trial was approved by the Institutional Review Boards of Johns Hopkins Medicine, 
the London School of Hygiene and Tropical Medicine, and the Malawi College of 
Medicine. 
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RESULTS 
Of 3040 individuals assessed for eligibility, 1842 were enrolled: 1001 in six clinics 
randomized to Xpert, and 841 in six clinics randomized to LED FM (Figure 1). Primary 
reasons for exclusion were residence outside a traceable area (n=583) and age <18 
years old (n=254). Participants in clinics randomized to Xpert versus LED FM were 
similar on most baseline characteristics, except that more participants in the LED FM 
arm reported either “poor” or “excellent” general health (Table 1). In the Xpert arm, 24 
participants (2.4%) were diagnosed with prevalent TB at enrollment (21 Xpert-positive, 
18 culture confirmed, 15 Xpert-positive and diagnosed within one week of enrollment, 
Figure 2), compared to 10 (1.2%) in the LED FM arm (10 smear-positive, nine culture 
confirmed, 10 smear-positive and diagnosed within one week) (p=0.06).  
 
Participants in the Xpert arm contributed 823 person-years of follow-up versus 697 in 
the LED FM arm (mean 0.82 versus 0.83 years per participant). Losses to follow-up 
before 350 days post-enrollment totaled 220 (22%) of 1001 in Xpert clinics and 187 
(22%) of 841 in LED FM clinics. Losses were similar (within 3%) across arms among 
patients with WHO stage III or IV disease, men, and patients ≤35 years old. During 
follow-up, 744 (74%) patients initiated ART in the Xpert arm, versus 609 (72%) in the 
LED FM arm. 
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As shown in Table 2, the cluster-adjusted rate of all-cause mortality was 22% lower in 
the Xpert arm (55 deaths, 6.7 per 100 person-years) than in the LED FM arm (58 
deaths, 8.6 per 100 person-years, rate ratio [RR] 0.78, 95% confidence interval [CI]: 
0.58–1.06); this difference was not statistically significant (p=0.10). Twelve (11%) of the 
113 deaths occurred after a diagnosis of TB (five in Xpert clinics, seven in LED FM 
clinics). Adjustment for age, sex, pregnancy status, and clinical stage had little effect on 
this primary result (adjusted RR 0.67, 95%CI: 0.44–1.01, p=0.06), as did exclusion of 
the clinic not originally part of the randomization (RR 0.77, 95%CI: 0.55–1.10, p=0.13). 
Very little heterogeneity was observed across clinics: the coefficient of variation for the 
primary analysis was <0.01. 
 
Subgroup analysis suggested that all-cause mortality was lower in clinics randomized to 
Xpert than in those randomized to LED FM among participants with more severe (WHO 
clinical stage III or IV) disease (RR 0.43, 95%CI: 0.22–0.87). There was little mortality 
difference among participants with less severe (stage I or II) HIV (RR 1.08, 95%CI: 
0.53–2.23, p-value for interaction = 0.24) (Figure 3). Most deaths occurred in 
participants with stage III/IV disease, between one and six months after enrollment 
(Figure 4). Mortality was lower in Xpert clinics randomized than in LED FM clinics 
among patients ≤35 years old (RR 0.40, 95%CI: 0.23-0.69) but not those >35 years old 
(RR 0.93, 95%CI: 0.43-2.02, p-value for interaction = 0.08). Mortality was also lower in 
the Xpert arm than in the LED FM arm among men (RR 0.58, 95%CI: 0.40–0.85); this 
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciy590/5060257
by University of Liverpool user
on 31 July 2018
 14 
 
difference was not statistically significant among women (RR 0.72, 95%CI: 0.32–1.63, 
p-value for interaction = 0.79).   
 
Excluding prevalent TB diagnosed at enrolment, the cluster-adjusted incidence of TB in 
the Xpert arm (8 cases, 1.1 per 100 person-years) was lower than in the LED FM arm 
(12 cases, 2.5 per 100 person-years, RR 0.45, 95%CI: 0.17–1.20), though this 
difference was not statistically significant (p=0.09). Of 54 total TB diagnoses, 15 (11 in 
the Xpert arm and four in the LED FM arm) were made through routine care outside of 
the study; nine of these routine diagnoses (eight in the Xpert arm and one in the LED 
FM arm) lacked microbiological confirmation. There were no confirmed cases of 
rifampin-resistant or multidrug-resistant TB. All patients diagnosed with TB by Xpert or 
LED FM were referred for treatment within one week, and all patients diagnosed with 
TB, except one in the LED FM arm, successfully initiated treatment.  
 
DISCUSSION 
In this cluster randomized trial across 12 primary health care clinics in rural Malawi, 
screening for TB symptoms at the time of HIV diagnosis followed by point-of-care Xpert 
(versus point-of-care LED fluorescence microscopy) did not significantly reduce all-
cause mortality over 12 months. However, screening with Xpert doubled the proportion 
of people diagnosed with prevalent TB and reduced all-cause mortality by 57% among 
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individuals presenting with stage III/IV disease, 42% among men, and 60% among 
those 35 years old or younger.  
 
To our knowledge, this is the first randomized trial of Xpert to show a meaningful 
reduction in all-cause mortality in readily identifiable subgroups. We also observed an 
increase in TB diagnoses at baseline of approximately similar magnitude, consistent 
with the hypothesis that Xpert is detecting individuals with active TB who are otherwise 
at high risk of death in the early ART period.19-22 In the LED FM arm, some individuals 
with prevalent TB at baseline were likely diagnosed later in the study period, when 
death was already imminent. Along with a trial of urine lipoarabinomannan (LAM) 
screening among hospitalized adults with TB symptoms,23 this is one of the first studies 
to demonstrate a mortality benefit to systematic screening for TB.24 By contrast, most 
other studies of systematic screening have focused on relatively healthy populations 
such as household contacts27 or residents of congregate settings such as mines28 or 
prisons29 and have not been powered to detect differences in mortality at the population 
level. Both of these trials suggest that TB screening may have greatest benefit for high-
risk populations, including hospitalized patients and individuals with advanced HIV and 
poor access to healthcare. 
 
Our observed mortality benefit differs from the findings of previous diagnostic trials, 
which include randomized trials of Xpert versus sputum smear microscopy5-9 and of risk 
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stratification and empirical TB treatment in patients with advanced HIV.25 This apparent 
discrepancy may reflect important differences in study design. First, we recruited 
patients with newly diagnosed HIV rather than patients with TB symptoms attending 
general diagnostic services. Second, we deliberately investigated rural clinics, 
anticipating higher barriers to accessing services such as radiology and empirical TB 
treatment. These services may mitigate the impact of Xpert by facilitating timely 
treatment of individuals testing false-negative for TB.26 Indeed, in contrast to prior 
studies, we observed more clinical diagnoses in the Xpert arm than in the LED FM arm, 
suggesting that the increased sensitivity of Xpert was not offset by fewer clinical 
diagnoses in this setting. Third, most prior studies performed Xpert at central 
laboratories, whereas we performed Xpert and LED FM directly in the clinic, aiming to 
provide results and initiate TB therapy (when indicated) on the same day.  
 
An important consideration is the substantial investment required to establish and 
maintain point-of-care TB screening services. In rural Malawi, introducing Xpert required 
developing infrastructure for solar electrical supply, positioning and continuous training 
of on-site personnel, and provision and maintenance of equipment and diagnostic 
supplies. Decisions about scale-up of Xpert-based screening must therefore balance 
the potential mortality benefit against these substantial implementation challenges. 
Importantly, Xpert can be performed to high standards by nurses in primary care 
clinics,5,8 and a more portable, robust, battery-operated Xpert platform (GeneXpert 
Omni) will be available,30 as may similar products from alternative manufacturers. In the 
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interim, decentralized HIV care clinics could aim to develop and strengthen specimen 
referral systems31 to provide rapid screening for TB (for example, concomitant with CD4 
testing) among people newly diagnosed with HIV in settings where on-site Xpert is not 
available. 
 
The results of this study should be interpreted in light of certain limitations. First, we 
were unable to reliably ascertain causes of death, and so cannot be certain that 
observed mortality differences between arms reflect differences in TB mortality. Second, 
due to a lower number of new HIV diagnoses than anticipated, we were only able to 
enroll approximately half of our target sample size, affecting study power. Third, 
participants were recruited after randomization of clusters, leading to potential 
identification bias, though our inclusion of all adults receiving new HIV diagnoses using 
few exclusion criteria may mitigate this concern. Fourth, while designed to be a 
pragmatic trial with minimal disturbance of routine clinical management (other than the 
intervention itself), implementation of point-of-care screening for TB required substantial 
support and changes to the existing infrastructure, as described above. Our results may 
therefore not fully generalize to settings in which such investments are not possible. 
Finally, our level of follow-up (mean 8.2 months of follow-up out of a desired 12) was 
lower than anticipated. While we did not see any evidence of differential losses to 
follow-up between our study arms, these results should nonetheless be interpreted in 
light of this incomplete follow-up. 
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In summary, this cluster randomized trial of point-of-care screening for tuberculosis 
among rural Malawian adults recently diagnosed with HIV showed no significant 
difference in 12-month all-cause mortality, comparing screening with Xpert MTB/RIF to 
LED fluorescence microscopy. However, all-cause mortality was 22% lower in the Xpert 
arm and was reduced even further among younger individuals, men, and those with 
more advanced disease. These findings suggest that, in settings with poor existing 
health infrastructure, screening for TB with a high-sensitivity test at the point of HIV 
diagnosis may save lives among those with highest risk of mortality and/or loss to 
clinical follow-up. Decisions about scale-up of this intervention should balance 
challenges in implementation and the lack of an observed benefit in the population as a 
whole against the need to prevent deaths among the highest-risk patients.  
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Table 1. Participant Characteristics at Enrolment 
 
 Characteristic Xpert Arm 
(n=1001) 
LED Arm  
(n=841) 
Age (in years, median/interquartile range) 33 (27-40) 32 (26-40) 
 
Gender 
     Male 
     Female (non-pregnant) 
     Female (pregnant) 
  
 
410 (41%) 
434 (43%) 
157 (16%) 
  
 
309 (37%) 
369 (44%) 
163 (19%) 
 
World Health Organization Clinical Stagea  
     1 or 2 
     3 or 4 
707 (71%) 
290 (29%) 
656 (79%) 
173 (21%) 
 
Self-reported General Health 
     Excellent 
     Good 
     Fair 
     Poor 
81 (8%) 
495 (49%) 
378 (38%) 
47 (5%) 
108 (13%) 
369 (44%) 
261 (31%) 
103 (12%) 
 
Smoking Status 
     Current 
 
 
125 (12%) 
 
 
104 (12%) 
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     Former 
     Never  
70 (7%) 
806 (81%) 
50 (6%) 
687 (82%) 
 
Previous Treatment for Tuberculosis 
     Yes 
     No 
 
 
24 (2%) 
977 (98%) 
 
 
15 (2%) 
826 (98%) 
 
Self-Reported Symptoms of Tuberculosis 
     Cough 
     Fever 
     Weight Loss 
     Night Sweats 
 
 
217 (22%) 
137 (14%) 
157 (16%) 
249 (25%) 
 
 
193 (23%) 
122 (15%) 
110 (13%) 
163 (19%) 
     Any Symptom 307 (31%) 258 (31%) 
 
a Clinical stage was not recorded in four participants in the Xpert arm and 12 in the LED 
FM arm; two of the 12 in the LED FM arm subsequently died. 
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Table 2. All-Cause Mortality by Clinic 
Study 
Wavea 
Clinic    
ID 
Deaths 
Observed 
Person-Years 
of Follow-Up 
Mortality 
Rate  
(per 100 
person-years) 
Summary 
Mortality Rateb 
(95% confidence 
interval) 
Xpert MTB/RIF Arm 
1 1A 17 270   6.23  
1 1B 12 154   7.78  
2 2A   8 130   6.17  
2 2D   9 132   6.84  
3 3B   2   30   6.60  
3 3D   7 102   6.86  
Total  55 818  6.74 (6.18-7.35) 
LED FM Arm 
1 1C 11 143   7.69  
1 1D 20 192 10.42  
2 2B   8 161   4.97  
2 2C   6   68   8.79  
3 3A   6   67   8.91  
4 3C   7   54 13.08  
Total  58 685  8.61 (6.13-12.11) 
LED FM, Light-emitting diode fluorescence microscopy 
a The study was conducted in three consecutive waves, each consisting of one year of 
enrolment followed by one year of follow-up. See Methods for further details. 
b Summary mortality rate in each arm, per 100 person-years, accounting for within-clinic 
correlation. 
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FIGURE LEGENDS 
 
Figure 1. Study Population 
* One clinic stopped offering HIV services prior to enrolling any participants and was 
replaced by the next-largest clinic. 
 
Figure 2. Patient Flow 
Shown are the numbers of patients in each arm who were successfully tested, tested 
positive, and started on treatment (either treatment for active TB or isoniazid preventive 
therapy). Of the 180 patients receiving valid LED FM results within a week, 174 (97%) 
had two smears performed, whereas six (3%) had only one. Numbers in the boxes at 
the bottom represent the total number of patients tested (and testing positive), including 
the initial baseline assessment and the one-year follow-up period. 
 
Figure 3. All-cause mortality in clinics randomized to Xpert versus LED FM 
Shown on the x-axis is the rate ratio for all-cause mortality in clinics randomized to 
Xpert versus light emitting diode fluorescence microscopy (LED FM) for TB screening 
among adults recently diagnosed with HIV in rural Malawi. Diamonds denote point 
estimates, horizontal lines denote 95% confidence intervals, and the vertical line 
represents no effect (rate ratio 1.0). The outcome in the entire population after 
adjustment for covariates (“Overall”) is shown at the bottom, with subgroup analyses 
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciy590/5060257
by University of Liverpool user
on 31 July 2018
 30 
 
and corresponding p-values for interaction shown above. Note that the primary study 
outcome, adjusted only for clinic (cluster), is not shown in this graph; rather, the 
covariate-adjusted overall outcome is shown for comparability to the pre-specified 
subgroup analyses, which were adjusted for both clinic and other covariates.  
 
 
Figure 4. Kaplan-Meier survival estimates, by study arm and clinical stage 
The y-axis shows survival according to study arm (Xpert versus LED FM) and clinical 
stage (stage I/II [less severe] versus stage III/IV [more severe]). The upper two (dashed) 
lines correspond to participants with stage I/II disease in the Xpert (blue) and LED FM 
(red) arms. The lower lines correspond to participants with stage III/IV disease in the 
Xpert and LED FM arms. Time is given in days. The majority of deaths occurred in 
those participants with stage III/IV disease, for whom diagnosis at a clinic randomized to 
Xpert was associated with lower all-cause mortality. 
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